Back to top
more

Eli Lilly (LLY)

(Real Time Quote from BATS)

$789.10 USD

789.10
1,384,878

+12.72 (1.64%)

Updated Nov 7, 2024 11:06 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Company News for Apr 18, 2024

by Zacks Equity Research

Companies In The Article are: LLY,ADSK,MBLY,USB

Eli Lilly's (LLY) Tirzepatide Meets Goals in Sleep Apnea Studies

by Zacks Equity Research

Data from Eli Lilly's (LLY) SURMOUNT-OSA studies show that treatment with tirzepatide results in a mean AHI reduction of up to 63% in adults with obstructive sleep apnea and obesity.

The Zacks Analyst Blog Highlights Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo

by Zacks Equity Research

Eli Lilly, Linde, Caterpillar, Salesforce, and Wells Fargo are included in this Analyst Blog.

Mark Vickery headshot

Top Research Reports for Eli Lilly, Linde & Caterpillar

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Linde plc (LIN) and Caterpillar Inc. (CAT).

Eli Lilly (LLY) Stock Dips While Market Gains: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Eli Lilly (LLY) stood at $749.26, denoting a -0.2% change from the preceding trading day.

Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?

by Zacks Equity Research

Sector ETF report for FHLC

Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?

by Zacks Equity Research

Sector ETF report for IHE

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

by Zacks Equity Research

Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Eli Lilly (LLY) Increases Despite Market Slip: Here's What You Need to Know

by Zacks Equity Research

Eli Lilly (LLY) reachead $761.98 at the closing of the latest trading day, reflecting a +0.63% change compared to its last close.

Biophytis (BPTS) to Begin Phase II Obesity Study, Stock Up

by Zacks Equity Research

Biophytis (BPTS) rises in the after-market hours as it announces the launch of a new clinical development program for its investigational candidate, BIO101, to treat obesity in combination with GLP-1 drugs.

Neena Mishra headshot

Healthcare ETFs for the Weight-Loss Drug Boom & Beyond

by Neena Mishra

We discuss attractive investment opportunities within the healthcare industry.

Zacks Market Edge Highlights: VICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly

by Zacks Equity Research

ICI Properties, KeyCorp, Meta Platforms, ExxonMobil and Eli Lilly are part of the Zacks Market Edge blog.

Tracey Ryniec headshot

How to Create a Stock Portfolio that Pays $100 a Month

by Tracey Ryniec

Forget buying a CD. Here's how to set yourself up with individual stocks that will net you passive income.

Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls

by Zacks Equity Research

Verve (VERV) stops enrollment in the phase Ib study of gene therapy candidate VERVE-10 to reduce disease-driving low-density lipoprotein cholesterol due to safety issues. Stock plunges on the news.

Eli Lilly (LLY) Ascends While Market Falls: Some Facts to Note

by Zacks Equity Research

The latest trading day saw Eli Lilly (LLY) settling at $763.96, representing a +0.45% change from its previous close.

The Zacks Analyst Blog Highlights Apple, NVIDIA, Eli Lilly, American Tower and McKesson

by Zacks Equity Research

Apple, NVIDIA, Eli Lilly, American Tower and McKesson are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Apple, NVIDIA & Eli Lilly

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), NVIDIA Corporation (NVDA) and Eli Lilly and Company (LLY).

Eli Lilly and Company (LLY) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Andrew Rocco headshot

2 Top Biotech Buyout Candidates

by Andrew Rocco

The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

Viking (VKTX) Up 17% on Encouraging Oral Obesity Drug Data

by Zacks Equity Research

Data from an early-stage study shows that patients who received Viking's (VKTX) orally-administered obesity drug lost up to 5.3% of their body weight after 28 days.

Amazon (AMZN) Expands Same-Day Medication Delivery Service

by Zacks Equity Research

Amazon (AMZN) expands same-day delivery of prescription medication to New York City and Los Angeles.

Eli Lilly (LLY) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

In the most recent trading session, Eli Lilly (LLY) closed at $774.90, indicating a +0.23% shift from the previous trading day.

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug

by Zacks Equity Research

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

Wall Street Awaits Consumer Confidence Data

by Zacks Equity Research

Wall Street Awaits Consumer Confidence Data

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.